Dr. Sara Lustigman, who leads Molecular Parasitology at the Lindsley F. Kimball Research Institute, will team up with Traverse Biotech Inc., which has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID).
Dr. Lustigman’s extensive academic research in immunology and infectious diseases will enable the evaluation of Traverse’s oral innate immunotherapy stimulant using validated preclinical pathogenic models.
Brandy Houser, co-founder and CEO of Traverse Biotech, expressed: “We are grateful for the support of NIAID. We believe that our product candidate has broad applicability to several immunological pathologies where myeloid-derived cells are dysfunctional and ultimately not effective in disease resolution.”